ID   BHP 2-7
AC   CVCL_6283
SY   BHP2-7; BHP-2
DR   BioSample; SAMN03151970
DR   Cosmic; 1005446
DR   Cosmic; 1094764
DR   Lonza; 783
DR   Wikidata; Q54796499
RX   PubMed=9253346;
RX   PubMed=18713817;
RX   PubMed=20143388;
RX   PubMed=21868764;
RX   PubMed=25365311;
RX   PubMed=29066502;
RX   PubMed=31443247;
CC   Problematic cell line: Contaminated. Shown to be a TPC-1 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764).
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00182.
CC   Population: Japanese.
CC   Sequence variation: Gene fusion; HGNC; 18782; CCDC6 + HGNC; 9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68fs (c.204_208delGGAGC); Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Gln1089Ter (c.3265C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line).
CC   Omics: Mitochondrial genome sequenced.
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): PubMed=18713817; PubMed=21868764; PubMed=25365311
ST   Amelogenin: X
ST   CSF1PO: 8,10 (PubMed=25365311)
ST   CSF1PO: 11,12 (PubMed=21868764)
ST   D13S317: 11,12
ST   D16S539: 9
ST   D18S51: 13,16
ST   D21S11: 30,31.2
ST   D3S1358: 16,17
ST   D5S818: 8,10
ST   D7S820: 9,11 (PubMed=25365311)
ST   D7S820: 11 (PubMed=21868764)
ST   FGA: 20,21
ST   TH01: 9 (PubMed=21868764)
ST   TH01: 11 (PubMed=25365311)
ST   TPOX: 11
ST   vWA: 14,18
DI   NCIt; C4035; Thyroid gland papillary carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_6298 ! TPC-1
SX   Female
AG   Adult
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 27
RX   PubMed=9253346; DOI=10.1210/jcem.82.8.4136;
RA   Ohta K., Pang X.-P., Berg L., Hershman J.M.;
RT   "Growth inhibition of new human thyroid carcinoma cell lines by
RT   activation of adenylate cyclase through the beta-adrenergic
RT   receptor.";
RL   J. Clin. Endocrinol. Metab. 82:2633-2638(1997).
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).
RX   PubMed=25365311; DOI=10.1210/jc.2014-2359;
RA   Garg M., Okamoto R., Nagata Y., Kanojia D., Venkatesan S., Anand M.T.,
RA   Braunstein G.D., Said J.W., Doan N.B., Ho Q., Akagi T., Gery S.,
RA   Liu L.-Z., Tan K.T., Chang W.J., Yang H., Ogawa S., Koeffler H.P.;
RT   "Establishment and characterization of novel human primary and
RT   metastatic anaplastic thyroid cancer cell lines and their genomic
RT   evolution over a year as a primagraft.";
RL   J. Clin. Endocrinol. Metab. 100:725-735(2015).
RX   PubMed=29066502; DOI=10.1530/ERC-17-0288;
RA   Corver W.E., Demmers J., Oosting J., Sahraeian S., Boot A., Ruano D.,
RA   van Wezel T., Morreau H.;
RT   "ROS-induced near-homozygous genomes in thyroid cancer.";
RL   Endocr. Relat. Cancer 25:83-97(2018).
RX   PubMed=31443247; DOI=10.3390/cancers11081185;
RA   Aydemirli M.D., Corver W.E., Beuk R., Roepman P.,
RA   Solleveld-Westerink N., van Wezel T., Kapiteijn E.H.W., Morreau H.;
RT   "Targeted treatment options of recurrent radioactive iodine refractory
RT   Hurthle cell cancer.";
RL   Cancers (Basel) 11:1185.1-1185.16(2019).